Top Markets
Coin of the day
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.

Recordati Industria Chimica e Farmaceutica S.p.A.

REC
Xếp hạng trong cổ phiếu #1792
Recordati Industria Chimica e Farmaceutica S.p.A., together with its... Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing’s syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fotivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, Vazkepa, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Combodart/Duodart; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Isturisa, for Cushing’s syndrome; Normosang, human hemin; Juxtapid, homozygous familial hypercholesterolemia;Ledaga, mycosis fungoides, T-cell cutaneous lymphoma;Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, treatments for the oral cavity; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. The company was founded in 1926 and is headquartered in Milan, Italy.
Giá cổ phiếu
$62.39
Vốn hóa thị trường
$12.69B
Thay đổi (1 ngày)
-0.19%
Thay đổi (1 năm)
6.33%
Quốc gia
IT
Giao dịch Recordati Industria Chimica e Farmaceutica S.p.A. (REC)

Danh mục

Lịch sử giá cổ phiếu của Recordati Industria Chimica e Farmaceutica S.p.A. (REC)
Giá đóng cửa cao nhất: $62.63 vào 2026-08-01

Giá đóng cửa thấp nhất: $0.31 vào 1995-01-01
Lịch sử giá cổ phiếu của Recordati Industria Chimica e Farmaceutica S.p.A. từ 1995 đến 2026
Hiệu suất giá cổ phiếu hàng năm
Năm Hiệu suất
2026 (TTM) 3.84%
2025 6.40%
2024 3.94%
2023 20.93%
2022 -31.57%
2021 15.77%
2020 30.61%
2019 24.94%
2018 -26.09%
2017 61.19%
2016 8.52%
2015 54.66%
2014 18.56%
2013 55.80%
2012 21.25%
2011 -18.52%
2010 15.93%
2009 44.92%
2008 -40.59%
2007 21.62%
2006 6.93%
2005 21.39%
2004 18.17%
2003 13.54%
2002 -14.02%
2001 110.27%
2000 144.44%
1999 -78.32%
1998 154.19%
1997 8.77%
1996 106.55%
1995 0.00%
Giá cổ phiếu của các công ty hoặc đối thủ tương tự
Công ty Giá cổ phiếu Thay đổi 1năm% Quốc gia
$59.08 64.74%
US
$49.68 72.50%
SE
$184.45 47.77%
FR
$113.04 53.61%
US
$0.63 -33.98%
HK